Neoadjuvant systemic treatment (NAST) is becoming increasingly popular to de-escalate the surgical extent and provide prognostic information to tailor systemic treatment after surgery, especially in triple-negative (TNBC) and HER2-positive breast cancer [3,4]. This evidence concerns the gene ERBB2 and breast cancer.